190 related articles for article (PubMed ID: 21612239)
21. Targeting of immunostimulatory DNA cures experimental visceral leishmaniasis through nitric oxide up-regulation and T cell activation.
Datta N; Mukherjee S; Das L; Das PK
Eur J Immunol; 2003 Jun; 33(6):1508-18. PubMed ID: 12778468
[TBL] [Abstract][Full Text] [Related]
22. Self-assembling CpG DNA nanoparticles for efficient antigen delivery and immunostimulation.
Rattanakiat S; Nishikawa M; Takakura Y
Eur J Pharm Sci; 2012 Sep; 47(2):352-8. PubMed ID: 22771546
[TBL] [Abstract][Full Text] [Related]
23. Mannose-Modified Liposome Co-Delivery of Human Papillomavirus Type 16 E7 Peptide and CpG Oligodeoxynucleotide Adjuvant Enhances Antitumor Activity Against Established Large TC-1 Grafted Tumors in Mice.
Zhao Y; Wang H; Yang Y; Jia W; Su T; Che Y; Feng Y; Yuan X; Wang X
Int J Nanomedicine; 2020; 15():9571-9586. PubMed ID: 33293808
[TBL] [Abstract][Full Text] [Related]
24. The enhanced antitumor-specific immune response with mannose- and CpG-ODN-coated liposomes delivering TRP2 peptide.
Lai C; Duan S; Ye F; Hou X; Li X; Zhao J; Yu X; Hu Z; Tang Z; Mo F; Yang X; Lu X
Theranostics; 2018; 8(6):1723-1739. PubMed ID: 29556352
[TBL] [Abstract][Full Text] [Related]
25. Immunostimulatory CpG motifs induce CTL responses to HIV type I oligomeric gp140 envelope protein.
Rao M; Matyas GR; Vancott TC; Birx DL; Alving CR
Immunol Cell Biol; 2004 Oct; 82(5):523-30. PubMed ID: 15479438
[TBL] [Abstract][Full Text] [Related]
26. Oligodeoxynucleotides without CpG motifs work as adjuvant for the induction of Th2 differentiation in a sequence-independent manner.
Sano K; Shirota H; Terui T; Hattori T; Tamura G
J Immunol; 2003 Mar; 170(5):2367-73. PubMed ID: 12594259
[TBL] [Abstract][Full Text] [Related]
27. Liposomal SLA co-incorporated with PO CpG ODNs or PS CpG ODNs induce the same protection against the murine model of leishmaniasis.
Shargh VH; Jaafari MR; Khamesipour A; Jaafari I; Jalali SA; Abbasi A; Badiee A
Vaccine; 2012 Jun; 30(26):3957-64. PubMed ID: 22465747
[TBL] [Abstract][Full Text] [Related]
28. Innovative strategies for co-delivering antigens and CpG oligonucleotides.
Krishnamachari Y; Salem AK
Adv Drug Deliv Rev; 2009 Mar; 61(3):205-17. PubMed ID: 19272328
[TBL] [Abstract][Full Text] [Related]
29. Improvement of the Nuclease Resistance and Immunostimulatory Activity of CpG Oligodeoxynucleotides by Conjugation to Sugar-Immobilized Gold Nanoparticles.
Murata K; Harayama K; Shimoda M; Niimura M; Wakao M; Suda Y; Moroishi T; Shinchi H
Bioconjug Chem; 2024 Jun; 35(6):804-815. PubMed ID: 38718344
[TBL] [Abstract][Full Text] [Related]
30. Liposomal CpG-ODN: An in vitro and in vivo study on macrophage subtypes responses, biodistribution and subsequent therapeutic efficacy in mice models of cancers.
Nikoofal-Sahlabadi S; Matbou Riahi M; Sadri K; Badiee A; Nikpoor AR; Jaafari MR
Eur J Pharm Sci; 2018 Jul; 119():159-170. PubMed ID: 29660463
[TBL] [Abstract][Full Text] [Related]
31. G3139 and other CpG-containing immunostimulatory phosphorothioate oligodeoxynucleotides are potent suppressors of the growth of human tumor xenografts in nude mice.
Gekeler V; Gimmnich P; Hofmann HP; Grebe C; Römmele M; Leja A; Baudler M; Benimetskaya L; Gonser B; Pieles U; Maier T; Wagner T; Sanders K; Beck JF; Hanauer G; Stein CA
Oligonucleotides; 2006; 16(1):83-93. PubMed ID: 16584297
[TBL] [Abstract][Full Text] [Related]
32. Non-Modified CpG Oligodeoxynucleotide Forming Guanine-Quadruplex Structure Complexes with ε-Poly-
Zhao D; Tu ATT; Shobo M; Le NBT; Yoshikawa C; Sugai K; Hakamata Y; Yamazaki T
Biomolecules; 2022 Dec; 12(12):. PubMed ID: 36551297
[TBL] [Abstract][Full Text] [Related]
33. Listeriolysin O-liposome-mediated cytosolic delivery of macromolecule antigen in vivo: enhancement of antigen-specific cytotoxic T lymphocyte frequency, activity, and tumor protection.
Mandal M; Lee KD
Biochim Biophys Acta; 2002 Jun; 1563(1-2):7-17. PubMed ID: 12007619
[TBL] [Abstract][Full Text] [Related]
34. Enhanced immune response to T-independent antigen by using CpG oligodeoxynucleotides encapsulated in liposomes.
Li WM; Bally MB; Schutze-Redelmeier MP
Vaccine; 2001 Oct; 20(1-2):148-57. PubMed ID: 11567759
[TBL] [Abstract][Full Text] [Related]
35. Immunostimulatory CpG oligodeoxynucleotides enhance the immune response to vaccine strategies involving granulocyte-macrophage colony-stimulating factor.
Liu HM; Newbrough SE; Bhatia SK; Dahle CE; Krieg AM; Weiner GJ
Blood; 1998 Nov; 92(10):3730-6. PubMed ID: 9808567
[TBL] [Abstract][Full Text] [Related]
36. Effective induction of anti-tumor immunity using p5 HER-2/neu derived peptide encapsulated in fusogenic DOTAP cationic liposomes co-administrated with CpG-ODN.
Mansourian M; Badiee A; Jalali SA; Shariat S; Yazdani M; Amin M; Jaafari MR
Immunol Lett; 2014 Nov; 162(1 Pt A):87-93. PubMed ID: 25086399
[TBL] [Abstract][Full Text] [Related]
37. Cationic liposomes containing soluble Leishmania antigens (SLA) plus CpG ODNs induce protection against murine model of leishmaniasis.
Heravi Shargh V; Jaafari MR; Khamesipour A; Jalali SA; Firouzmand H; Abbasi A; Badiee A
Parasitol Res; 2012 Jul; 111(1):105-14. PubMed ID: 22223037
[TBL] [Abstract][Full Text] [Related]
38. Reduction Sensitive PEG Hydrogels for Codelivery of Antigen and Adjuvant To Induce Potent CTLs.
Kapadia CH; Tian S; Perry JL; Luft JC; DeSimone JM
Mol Pharm; 2016 Oct; 13(10):3381-3394. PubMed ID: 27551741
[TBL] [Abstract][Full Text] [Related]
39. Lipid Nanoparticle Delivery Alters the Adjuvanticity of the TLR9 Agonist CpG by Innate Immune Activation in Lymphoid Tissue.
Zhong Z; Chen Y; Deswarte K; Lauwers H; De Lombaerde E; Cui X; Van Herck S; Ye T; Gontsarik M; Lienenklaus S; Sanders NN; Lambrecht BN; De Koker S; De Geest BG
Adv Healthc Mater; 2023 Dec; 12(32):e2301687. PubMed ID: 37772637
[TBL] [Abstract][Full Text] [Related]
40. Differential immune activation following encapsulation of immunostimulatory CpG oligodeoxynucleotide in nanoliposomes.
Erikçi E; Gursel M; Gürsel I
Biomaterials; 2011 Feb; 32(6):1715-23. PubMed ID: 21112627
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
